2.50
Hdl Handle:
http://hdl.handle.net/10541/75816
Title:
Targeted antitumour therapy--future perspectives.
Authors:
Ranson, Malcolm R; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
The advent of targeted therapy presents an unprecedented opportunity for advances in the treatment of cancer. A key challenge will be to translate the undoubted promise of targeted agents into tangible clinical benefits. Achieving this goal is likely to be dependent upon a number of factors. These include continued research to improve our understanding of the heterogeneity and complexity of the tumour microenvironment; refinement of clinical trial design to incorporate nontraditional end points such as the optimum biological dose and health-related quality of life; and the use of technological advancements in proteomics, genomics and biomarker development to better predict tumour types and patient subsets that may be particularly responsive to treatment, as well as enable a more accurate assessment of drug effect at the molecular level. In summary, the future success of targeted agents will require an integrated multidisciplinary approach involving all stakeholders.
Affiliation:
Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. malcolm.ranson@man.ac.uk
Citation:
Targeted antitumour therapy--future perspectives. 2005, 92 Suppl 1:S28-31 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Jun-2005
URI:
http://hdl.handle.net/10541/75816
DOI:
10.1038/sj.bjc.6602606
PubMed ID:
15928656
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRanson, Malcolm R-
dc.contributor.authorJayson, Gordon C-
dc.date.accessioned2009-07-29T10:57:09Z-
dc.date.available2009-07-29T10:57:09Z-
dc.date.issued2005-06-
dc.identifier.citationTargeted antitumour therapy--future perspectives. 2005, 92 Suppl 1:S28-31 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid15928656-
dc.identifier.doi10.1038/sj.bjc.6602606-
dc.identifier.urihttp://hdl.handle.net/10541/75816-
dc.description.abstractThe advent of targeted therapy presents an unprecedented opportunity for advances in the treatment of cancer. A key challenge will be to translate the undoubted promise of targeted agents into tangible clinical benefits. Achieving this goal is likely to be dependent upon a number of factors. These include continued research to improve our understanding of the heterogeneity and complexity of the tumour microenvironment; refinement of clinical trial design to incorporate nontraditional end points such as the optimum biological dose and health-related quality of life; and the use of technological advancements in proteomics, genomics and biomarker development to better predict tumour types and patient subsets that may be particularly responsive to treatment, as well as enable a more accurate assessment of drug effect at the molecular level. In summary, the future success of targeted agents will require an integrated multidisciplinary approach involving all stakeholders.en
dc.language.isoenen
dc.subjectCanceren
dc.subjectTumour Markersen
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshBiomedical Research-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshForecasting-
dc.subject.meshHumans-
dc.subject.meshNeoplasms-
dc.subject.meshQuality of Life-
dc.subject.meshResearch Design-
dc.subject.meshTumor Markers, Biological-
dc.titleTargeted antitumour therapy--future perspectives.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. malcolm.ranson@man.ac.uken
dc.identifier.journalBritish Journal of Canceren
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.